The trade-off between population and individual benefit of screening.
In cancer screening there is a delicate balance between the benefit for the population and the individual benefit. In different European mammography and other screening programmes major differences were observed regarding detection rates and false positive rates. With massive screening programmes starting in Germany, careful evaluation of their performance and achievement is mandatory, including a determination of the false negative rates. This requires the determination of interval cancer rates on the basis of complete population-based cancer registries.